223 related articles for article (PubMed ID: 16051786)
21. Staying ahead of the fourth horseman.
Rex JH
Nat Rev Microbiol; 2004 Sep; 2(9):684. PubMed ID: 15378807
[No Abstract] [Full Text] [Related]
22. The winding road from ideas to income.
Wadman M
Nature; 2008 Jun; 453(7197):830-1. PubMed ID: 18548029
[No Abstract] [Full Text] [Related]
23. [Drug development costs are overstated by the industry].
Jeppsson A
Lakartidningen; 2006 Mar 1-7; 103(9):663-4; discussion 664. PubMed ID: 16583545
[No Abstract] [Full Text] [Related]
24. Productivity counts--but the definition is key.
Mervis J
Science; 2005 Jul; 309(5735):726. PubMed ID: 16051784
[No Abstract] [Full Text] [Related]
25. Implications of pharmacogenomics for drug development.
Kirk RJ; Hung JL; Horner SR; Perez JT
Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
[TBL] [Abstract][Full Text] [Related]
26. The antibiotic pipeline--challenges, costs, and values.
Wenzel RP
N Engl J Med; 2004 Aug; 351(6):523-6. PubMed ID: 15295041
[No Abstract] [Full Text] [Related]
27. Drug discovery.
Kennedy D
Science; 2004 Mar; 303(5665):1729. PubMed ID: 15031461
[No Abstract] [Full Text] [Related]
28. Hit and Lead identification: efficient practices for drug discovery.
Goodnow RA; Gillespie P
Prog Med Chem; 2007; 45():1-61. PubMed ID: 17280901
[No Abstract] [Full Text] [Related]
29. Improved early clinical development through human microdosing studies.
Wilding IR; Bell JA
Drug Discov Today; 2005 Jul; 10(13):890-4. PubMed ID: 15993808
[No Abstract] [Full Text] [Related]
30. Attrition and translation.
Duyk G
Science; 2003 Oct; 302(5645):603-5. PubMed ID: 14576424
[TBL] [Abstract][Full Text] [Related]
31. Ghost story: at medical journals, writers paid by industry play big role.
Mathews AW
Wall St J (East Ed); 2005 Dec; ():A1, A8. PubMed ID: 16506304
[No Abstract] [Full Text] [Related]
32. Financial interests constrain drug development.
Garattini S
Science; 1997 Jan; 275(5298):287. PubMed ID: 9005546
[No Abstract] [Full Text] [Related]
33. Growth industry.
Lewis R
Nature; 2004 Mar; 428(6980):348-9. PubMed ID: 15029202
[No Abstract] [Full Text] [Related]
34. Conflicts of interest in medical research: how much conflict should exceed legal boundaries?
Klanica K
J Biolaw Bus; 2005; 8(3):37-45. PubMed ID: 16459426
[TBL] [Abstract][Full Text] [Related]
35. China rushes through major funding system.
Cyranoski D
Nature; 2008 Sep; 455(7210):142. PubMed ID: 18784681
[No Abstract] [Full Text] [Related]
36. [Drug development--from receptor research to therapy].
Lammintausta R; Scheinin M
Duodecim; 1998; 114(10):957-66. PubMed ID: 11524784
[No Abstract] [Full Text] [Related]
37. Seeing the big picture.
Hoag H
Nature; 2006 Apr; 440(7087):1084-5. PubMed ID: 16683304
[No Abstract] [Full Text] [Related]
38. Researchers facing increasing costs for clinical research, with few solutions.
Erdmann J
J Natl Cancer Inst; 2005 Oct; 97(20):1492-4. PubMed ID: 16234558
[No Abstract] [Full Text] [Related]
39. Trust, but verify.
Nature; 2009 Sep; 461(7262):315. PubMed ID: 19759574
[No Abstract] [Full Text] [Related]
40. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
